ClinicalTrials.gg
RecruitingNCT07342803Updated Jan 15, 2026

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

A Phase 2 interventional study of LP-003 Injection and Omalizumab in Allergic Asthma, sponsored by Longbio Pharma. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Longbio Pharma · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2025, registered Dec 2025).
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
92nd of 182
200 · median 203
Started
2025
with 31 others
Phase 2
39 of 251
19 open now
Primary completion
2027-12
later than 64 of 95 live
Registered
220th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 92nd largest by planned enrollment of the 182 interventional ones that give a count, is one of 32 that started in 2025, is one of 39 in phase 2, reaches primary completion later than 64 of the 95 other live ones, and was the 220th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.

03

Conditions studied

  • Allergic Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and ≤ 75 years, no gender restriction;
  2. Body weight ≥ 40 kg;
  3. Diagnosed with bronchial asthma for at least 1 year according to the "Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition)", and diagnosed with allergic asthma according to the "Chinese Guidelines for the Diagnosis and Treatment of Allergic Asthma (2019 Edition)" ; At least 1 asthma exacerbation in the year prior to screening (referring to GINA and Chinese guidelines, asthma exacerbation is defined as worsening of asthma symptoms requiring systemic treatment for at least 3 days, and/or multiplying the dose of inhaled glucocorticoids for at least 3 days);
  4. Positive bronchial dilation test within 24 months prior to screening or at the time of screening;
  5. Subjects with at least one positive skin prick test or positive serum specific IgE test result for a relevant allergen within 12 months prior to randomization;
  6. Subjects who have received medium to high dose inhaled corticosteroids (ICS) treatment for at least 8 weeks prior to screening (fluticasone propionate >250 μg/day or equivalent dose of ICS, not exceeding fluticasone propionate 2000 μg/day or equivalent dose of ICS, as per the "Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition)"), have maintained stable use for 4 weeks before randomization, with asthma remaining partially controlled or uncontrolled (defined as ACT score ≤ 19);
  7. Combined with at least one other asthma control medication (long-acting β2 receptor agonists (LABA), long-acting muscarinic antagonists (LAMA), leukotriene receptor antagonists (LTRA), and sustained-release theophylline treatment) and stable use for 4 weeks before randomization ;
  8. At screening, 40% \< \< 80% of predicted value;
  9. Subjects who have no plans for pregnancy and agree to take effective measures during the trial and for 6 months after the last dose of study treatment;
  10. Subjects who voluntarily sign the ICF, are able to understand and correctly fill out the assessment form, correctly use the PEF device and record the patient diary card, and attend follow-up visits as scheduled.Male or female, aged 18 to 75 years.

Exclusion criteria

Exclusion Criteria:

  1. Allergic to the product and its or Xolair® ;
  2. Coexisting diseases other than asthma that may affect lung function, such as (COPD), allergic bronchopulmonary aspergillosis (ABPA), and bronchiectasis, which, in the investigator's judgment, may place the subject at inappropriate risk or affect the assessment of study results;
  3. Patients who have severe or uncontrolled diseases of the liver, kidneys, gastrointestinal tract, cardiovascular and cerebrovascular systems, hematopoietic system, urogenital system, endocrine system, nervous system, immune system, etc.;
  4. infection history within 4 weeks prior to randomization, as assessed by the investigator, affecting patient evaluation;
  5. Major surgery within 4 weeks prior to randomization or planned surgical procedures during the study period, or treatments that the investigator believes may affect patient evaluation;
  6. Known parasitic infection within 6 months prior to randomization;
  7. History of diagnosed within 5 years prior to screening;
  8. Clinically significant abnormalities in laboratory tests during the screening period and baseline, deemed unsuitable for participation by the investigator ;
  9. Positive test for (HIV) antibodies at screening, or positive for treponema pallidum antibodies (except RPR or TRUST negative), or positive for surface antigen (except HBV-DNA below the detection limit of the site), or positive for hepatitis B core antibody (except HBV-DNA below the detection limit of the site), or positive for virus (HCV) antibodies (except HCV RNA below the detection limit of the site);
  10. Still smoking or having quit smoking for less than 6 months at screening, or a history of smoking ≥10 pack-years [Smoking Index (pack-years) = daily smoking amount (packs) × smoking duration (years), 1 pack = 20 cigarettes];
  11. Used biological agents such as monoclonal antibodies, including investigational biological agents, within 3 months prior to screening or within 5 half-lives of the drug (whichever is longer);
  12. Received systemic or systemic (dose equivalent to prednisone >10 mg/day) for inflammatory or diseases (such as rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, etc.) within 8 weeks prior to screening or within 5 half-lives of the drug (whichever is longer);
  13. Specific allergen immunotherapy conducted within 3 months prior to screening;
  14. Live (attenuated) virus/bacterial vaccines administered or intravenous immunoglobulin used within 4 weeks prior to screening;
  15. Participation in other drug clinical trials within 3 months or 5 half-lives of the drug (whichever is longer) prior to screening;
  16. History of drug abuse, substance abuse, and/or excessive alcohol consumption within 1 year prior to screening;
  17. Pregnant or breastfeeding women;
  18. Any other condition that makes the subject unsuitable for participation in the trial as assessed by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    LP-003 150 mg group

    Participants received subcutaneous injections of LP-003 or Placebo every 4 weeks.

    Biological: LP-003 Injection · Biological: Placebo

  • Experimental
    LP-003 300 mg group

    Participants received subcutaneous injections of LP-003 or Placebo every 4 weeks.

    Biological: LP-003 Injection · Biological: Placebo

  • Experimental
    LP-003 450 mg group

    Participants received subcutaneous injections of LP-003 or Placebo every 4 weeks.

    Biological: LP-003 Injection · Biological: Placebo

  • Active comparator
    Omalizumab group

    Participants received subcutaneous injection of Omalizumab every 4 weeks; the dose was determined by baseline IgE level and body weight, with a maximum dose 600 mg.

    Biological: Omalizumab

  • Placebo comparator
    Placebo group

    Participants received subcutaneous injection of Placebo every 4 weeks.

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean number of asthma exacerbations per subject

    Time frame: During the 24-week treatment period

  2. Proportion of subjects with asthma exacerbations

    Time frame: During the 24-week treatment period

  3. Mean number of asthma exacerbations per subject

    Time frame: During the 36-week and 48-week follow-up period

  4. Proportion of subjects with asthma exacerbations

    Time frame: During the 36-week and 48-week follow-up period

  5. Proportion of subjects with loss of asthma control (LOAC) in each group

    Time frame: During the 24-week treatment period

  6. Incidence of adverse events (AEs)

    Time frame: Up to approximately 52 weeks

  7. Change from baseline in pre-bronchodilator FEV1, FVC, and FEV1/FVC ratio

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  8. Change from baseline in weekly mean daily and weekly Peak Expiratory Flow (PEF) variability, and change from baseline in mean PEF

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  9. Time to first asthma exacerbation from baseline

    Time frame: Up to approximately 52 weeks

  10. Change from baseline in weekly use of reliever medication (Salbutamol Sulfate Aerosol)

    Time frame: Up to approximately 52 weeks

  11. Change from baseline in weekly Asthma Symptom Diary Score

    Time frame: Up to approximately 52 weeks

  12. Change from baseline in standardized Asthma Quality of Life Questionnaire (AQLQ(S))

    The AQLQ(S) is a validated patient-reported outcome (PRO) tool designed to assess the impact of asthma on patients' quality of life. This questionnaire consists of a total of 35 items, which are scored on a 7-point Likert scale (where 1 indicates the worst quality of life and 7 indicates the best quality of life).

    Time frame: Weeks 12 and 24

  13. Change from baseline in Asthma Control Questionnaire (ACQ-5)

    The ACQ-5 is a tool for evaluating asthma control status. The questionnaire comprises 5 items, with the ACQ-5 score calculated as the mean score of the 5 items. A score of \< 0.75 indicates complete asthma control, a score between 0.75 and 1.5 indicates well-controlled asthma, and a score of \> 1.5 indicates uncontrolled asthma.

    Time frame: Weeks 12 and 24

  14. Change from baseline in Asthma Control Test (ACT)

    The ACT is a tool for assessing asthma control status, comprising 5 questions with 5 response options each (scored 1 to 5 points per question). The total score is the sum of the 5 items, with the following criteria: 20-25 = well-controlled; 16-19 = inadequately controlled; 5-15 = very poorly controlled.

    Time frame: Weeks 12 and 24

  15. Change in serum free IgE levels over time at different time points

    Time frame: Up to approximately 52 weeks

  16. Serum concentrations of LP-003 at different time points

    Time frame: Up to approximately 52 weeks

  17. Incidence of Anti-drug Antibodies (ADA)

    Time frame: Up to approximately 52 weeks

Secondary outcomes

  1. Change from baseline in Fractional exhaled Nitric Oxide (FeNO)

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  2. Change from baseline in blood eosinophil count (EOS)

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  3. Change in serum total IgE levels over time at different time points

    Time frame: Up to approximately 52 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 35 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 15, 2026
StartActual
Jan 25, 2025
Primary completionEst.
Dec 28, 2027
CompletionEst.
Sep 30, 2029
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07342803
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Jan 25, 2025
Primary completion
Dec 28, 2027 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Jan 15, 2026

Study contacts

Jie Yang
Contact
yangj@longbiopharma.com
+86 021-58372390
Jieming Qu
principal investigator · Ruijin Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-003

Start the discussion